GPX4 and neoplasm: In an in vivo model, using tumors xenograft with breast cancer cell lines in mouse, GPX4 inhibitors plus anti-PD-1-antibody significantly inhibited tumor growth compared with therapy with anti-PD-1 therapy alone.